For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
The TrumpRx medicine will prove worse than the disease
On September 30, President Trump, standing alongside the CEO of Pfizer, announced a multifaceted deal wherein Pfizer would inoculate itself from new regulations and…
Blog
Free the Economy podcast: Obamacare problems with Jeremy Nighohossian
In this week’s episode we talk about the unintended consequences of the Sarbanes-Oxley Act of 2002, decarbonization of economic growth, and resources…
Blog
The problem with Obamacare is Obamacare
This year, the COVID-induced expansion of the Affordable Care Act (ACA) will expire. Extending the expanded subsidies has become a point of contention between Republicans…
Search Posts
Blog
Can AI thrive in health care’s HIPAA-shaped box?
Innovation continues to transform health care, enabling us to live longer and healthier lives. And now artificial intelligence (AI) is poised to supercharge that…
The Wall Street Journal
The FTC Goes Evidence-Free
Through three years of Lina Khan’s leadership, the Federal Trade Commission has suffered an unprecedented streak of high-profile court defeats. That’s because the agency regularly makes…
Blog
This week in ridiculous regulations: Blood donors and paper marketing
Donald Trump survived an assassination attempt. The Republicans held their convention in Milwaukee. Sen. Robert Menendez (D-NJ) was convicted on bribery charges and resigned, leaving…
Blog
Missing the economists in FTC’s latest PBM study
The Federal Trade Commission (FTC) released its not-so-objectively titled interim report on Pharmacy Benefit Managers (PBMs): Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa Holyoak…
Penn Live
Harrisburg is taking a wrong approach to drug pricing | PennLive letters
CEI’s Joel Zinberg was cited in a Penn Live article on Pharmacy Benefit Managers: Joel Zinberg from the Competitive Enterprise Institute (CEI) explains, “PBMs enhance…